DARE Key Statistics, Chart & Performance
The current stock price of DARE is 1.84 USD. In the past month the price decreased by -10.4%. In the past year, price decreased by -47.15%.
DARE Latest News, Press Relases and Analysis
DARE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.91 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 19.93 | 498.33B | ||
| MRK | MERCK & CO. INC. | 11.9 | 261.84B | ||
| PFE | PFIZER INC | 8.04 | 146.35B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.5 | 100.14B | ||
| ZTS | ZOETIS INC | 20.22 | 56.81B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.74 | 23.34B | ||
| VTRS | VIATRIS INC | 4.59 | 12.46B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.24 | 11.56B | ||
| CORT | CORCEPT THERAPEUTICS INC | 90.23 | 8.35B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.56B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.80B |
Related stock screener links
About DARE
Company Profile
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 21 full-time employees. The company went IPO on 2014-04-10. The firm's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
Company Info
DARE BIOSCIENCE INC
3655 Nobel Dr Ste 260
San Diego CALIFORNIA 92122 US
CEO: Sabrina Martucci Johnson
Employees: 22
Phone: 18589267655
DARE BIOSCIENCE INC / DARE FAQ
Can you describe the business of DARE BIOSCIENCE INC?
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. The company is headquartered in San Diego, California and currently employs 21 full-time employees. The company went IPO on 2014-04-10. The firm's programs target unmet needs in women's health, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. Its product includes XACIATO (clindamycin phosphate) vaginal gel 2%. XACIATO is a single-dose prescription medication for the treatment of bacterial vaginosis in females 12 years of age and older. Its other product candidates include Ovaprene, Sildenafil Cream, and DARE-HRT1. Ovaprene is an investigational, hormone-free, monthly intravaginal contraceptive. Sildenafil Cream is a novel cream formulation of sildenafil for the treatment of female sexual arousal disorder; and DARE-HRT1 is an intravaginal ring designed to deliver a combination of menopausal hormone therapy, bio-identical 17b-estradiol and progesterone together, continuously over a 28-day period for the treatment of moderate to severe vasomotor symptoms, also known as hot flashes.
What is the stock price of DARE BIOSCIENCE INC today?
The current stock price of DARE is 1.84 USD. The price increased by 1.66% in the last trading session.
What is the dividend status of DARE BIOSCIENCE INC?
DARE does not pay a dividend.
What is the ChartMill technical and fundamental rating of DARE stock?
DARE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting DARE stock to perform?
10 analysts have analysed DARE and the average price target is 10.97 USD. This implies a price increase of 495.92% is expected in the next year compared to the current price of 1.84.
Would investing in DARE BIOSCIENCE INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DARE.
What is DARE BIOSCIENCE INC worth?
DARE BIOSCIENCE INC (DARE) has a market capitalization of 24.80M USD. This makes DARE a Nano Cap stock.
DARE Technical Analysis
DARE Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DARE. DARE may be in some trouble as it scores bad on both profitability and health.
DARE Financial Highlights
Over the last trailing twelve months DARE reported a non-GAAP Earnings per Share(EPS) of -1.88. The EPS decreased by -218.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
DARE Forecast & Estimates
10 analysts have analysed DARE and the average price target is 10.97 USD. This implies a price increase of 495.92% is expected in the next year compared to the current price of 1.84.
For the next year, analysts expect an EPS growth of -204.04% and a revenue growth -61.82% for DARE